Safety and efficacy of eplerenone in patients at high risk for hyperkalemia and/or worsening renal function: analyses of the EMPHASIS-HF study subgroups (Eplerenone in Mild Patients Hospitalization And SurvIval Study in Heart Failure).

[1]  Akshay S. Desai,et al.  Influence of baseline and worsening renal function on efficacy of spironolactone in patients With severe heart failure: insights from RALES (Randomized Aldactone Evaluation Study). , 2012, Journal of the American College of Cardiology.

[2]  J. McMurray,et al.  Eplerenone and new‐onset diabetes in patients with mild heart failure: results from the Eplerenone in Mild Patients Hospitalization and Survival Study in Heart Failure (EMPHASIS‐HF) , 2012, European journal of heart failure.

[3]  L. A. Bonet,et al.  ESC Guidelines for the diagnosis and treatment of acute and chronic heart failure 2012 , 2012, Turk Kardiyoloji Dernegi arsivi : Turk Kardiyoloji Derneginin yayin organidir.

[4]  C. Szeto,et al.  Mineralocorticoid Receptor Antagonist for Renal Protection , 2012, Renal failure.

[5]  K. Dickstein,et al.  Aliskiren, ALTITUDE, and the implications for ATMOSPHERE , 2012, European journal of heart failure.

[6]  M. Dupont,et al.  CONTEMPORARY ADMINISTRATION OF ALDOSTERONE RECEPTOR ANTAGONISTS IN PATIENTS HOSPITALIZED WITH CONGESTIVE HEART FAILURE AFTER EMPHASIS-HF , 2012 .

[7]  M. Pfisterer,et al.  Frequency and predictors of hyperkalemia in patients ≥60 years of age with heart failure undergoing intense medical therapy. , 2012, The American journal of cardiology.

[8]  J. McMurray,et al.  Eplerenone in patients with systolic heart failure and mild symptoms. , 2011, The New England journal of medicine.

[9]  E. Lakatta,et al.  Elevated Mineralocorticoid Receptor Activity in Aged Rat Vascular Smooth Muscle Cells Promotes a Proinflammatory Phenotype via Extracellular Signal-Regulated Kinase 1/2 Mitogen-Activated Protein Kinase and Epidermal Growth Factor Receptor–Dependent Pathways , 2010, Hypertension.

[10]  J. McMurray,et al.  Rationale and design of the Eplerenone in Mild Patients Hospitalization And SurvIval Study in Heart Failure (EMPHASIS‐HF) , 2010, European journal of heart failure.

[11]  Robert W Platt,et al.  Predicting the risk of hyperkalemia in patients with chronic kidney disease starting lisinopril , 2010, Pharmacoepidemiology and drug safety.

[12]  C. Yancy,et al.  Use of aldosterone antagonists in heart failure. , 2009, Journal of the American Medical Association (JAMA).

[13]  M. Pfisterer,et al.  BNP-guided vs symptom-guided heart failure therapy: the Trial of Intensified vs Standard Medical Therapy in Elderly Patients With Congestive Heart Failure (TIME-CHF) randomized trial. , 2009, JAMA.

[14]  C. O’loughlin,et al.  Multiple neurohumoral modulating agents in systolic dysfunction heart failure: are we lowering blood pressure too much? , 2008, Journal of cardiac failure.

[15]  A. Stuck,et al.  Age-dependent Decrease in 11 β-Hydroxysteroid Dehydrogenase Type 2 ( 11 β-HSD 2 ) Activity in Hypertensive Patients , 2008 .

[16]  A. Kshirsagar,et al.  Change in proteinuria after adding aldosterone blockers to ACE inhibitors or angiotensin receptor blockers in CKD: a systematic review. , 2008, American journal of kidney diseases : the official journal of the National Kidney Foundation.

[17]  R. Bigazzi,et al.  Long-term effects of spironolactone on proteinuria and kidney function in patients with chronic kidney disease. , 2006, Kidney international.

[18]  J. McMurray,et al.  Treatment of heart failure with spironolactone--trial and tribulations. , 2004, The New England journal of medicine.

[19]  A. Laupacis,et al.  Rates of Hyperkalemia after Publication of the Randomized Aldactone Evaluation Study , 2004 .

[20]  B. Pitt,et al.  Eplerenone, a selective aldosterone blocker, in patients with left ventricular dysfunction after myocardial infarction. , 2003, The New England journal of medicine.

[21]  B. Pitt,et al.  The Effect of Spironolactone on Morbidity and Mortality in Patients with Severe Heart Failure , 2000 .

[22]  J. Funder.  Aldosterone and mineralocorticoid receptors: orphan questions. , 2000, Kidney international.

[23]  B. Pitt,et al.  The effect of spironolactone on morbidity and mortality in patients with severe heart failure. Randomized Aldactone Evaluation Study Investigators. , 1999, The New England journal of medicine.

[24]  P. Weidmann,et al.  Effect on aging on plasma renin and aldosterone in normal man. , 1975, Kidney international.